Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology
Overview
Affiliations
Tau protein, a neuronal microtubule-associated protein, becomes hyperphosphorylated in several neurodegenerative diseases called tauopathies. Hyperphosphorylation of tau is correlated to its redistribution from the axon to the somato-dendritic compartment at early stages of tauopathies. Interestingly, tau hyperphosphorylation begins in different regions of the brain in each tauopathy. In some regions, both neurons and glial cells develop tau hyperphosphorylation. Tau hyperphosphorylation is also observed in physiological conditions such as hibernation and brain development. In the first section of present article, we will review the spatiotemporal and cellular distribution of hyperphosphorylated tau in the most frequent tauopathies. In the second section, we will compare the pattern of tau hyperphosphorylation in physiological and pathological conditions and discuss the sites that could play a pivotal role in the conversion of non-toxic to toxic forms of hyperphosphorylated tau. Furthermore, we will discuss the role of hyperphosphorylated tau in physiological and pathological conditions and the fact that tau hyperphosphorylation is reversible in physiological conditions but not in a pathological ones. In the third section, we will speculate how the differences and similarities between hyperphosphorylated tau in physiological and pathological conditions could impact the elaboration of therapies to prevent tau pathology. In the fourth section, the different therapeutic approaches using tau as a direct or indirect therapeutic target will be presented.
Torpor induces reversible tau hyperphosphorylation and accumulation in mice expressing human tau.
de Veij Mestdagh C, Witte M, Scheper W, Smit A, Henning R, Van Kesteren R Acta Neuropathol Commun. 2024; 12(1):86.
PMID: 38835043 PMC: 11149198. DOI: 10.1186/s40478-024-01800-4.
Recent insights from non-mammalian models of brain injuries: an emerging literature.
Katchur N, Notterman D Front Neurol. 2024; 15:1378620.
PMID: 38566857 PMC: 10985199. DOI: 10.3389/fneur.2024.1378620.
Brain pathology and symptoms linked to concussion history: beyond chronic traumatic encephalopathy.
Taskina D, Zhu C, Schwab N, Hazrati L Brain Commun. 2024; 6(2):fcad314.
PMID: 38560515 PMC: 10977958. DOI: 10.1093/braincomms/fcad314.
Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K, Owecki W, Jankowski J, Surdacka A Int J Mol Sci. 2024; 25(2).
PMID: 38256241 PMC: 10817083. DOI: 10.3390/ijms25021168.
Khalilpour J, Zangbar H, Alipour M, Pakdel F, Zavari Z, Shahabi P Mol Neurobiol. 2023; 61(6):3121-3143.
PMID: 37976025 DOI: 10.1007/s12035-023-03763-4.